Biomind Labs to Argument Which Psychedelic Medicines Will Lead the Industry Into Its Next Phase of Evolution at The National Gallery in London

Biomind Labs Inc. (“Biomind Labs” or the “Company”), a leading biotech company developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce that its CEO Alejandro Antalich will be debating in the “PSYCH Symposium: London 2022 – Unlocking the potential of psychedelic Healthcare” to be held at The National Gallery next Wednesday, May 11, 2022.

Latest Aithority Insights : Opsera Announces Partnership with Mindtree to Accelerate DevOps Initiatives

Alejandro Antalich, CEO of Biomind Labs commented: “The PSYCH Symposium will be one of the most relevant events in the psychedelic industry in 2022, and this is the reason why we have decided to be part of the debates with the principal leaders of the sector and use this forum to argument why we believe we have taken one of the best approaches within the sector as a pharmaceutical company.

Browse The Complete News About Aithority : TeamViewer and SAP Join Forces to Digitalize Warehouse Operations with Augmented Reality

Last year Prime Minister Boris Johnson said that he will examine the latest advice on the legalization of a psychedelic drug. We must confess that with this statement, Prime Minister Johnson won our respect because as a leader of a nation, he displayed empathy towards millions of patients that suffer from any kind of mental health disorder, and this kind of attitude is what is needed from global leaders.

We support the initiative of Mr. Crispin Blunt that has had a positive impact on Prime Minister Johnson, with the hope of promoting a global analysis and review of psychedelic legalization by government authorities, regulators and the psychiatry community. While more clinical research must be done, time is becoming critical for the almost one billion people that are affected by mental disorders”, concluded Mr. Antalich.

Read More About Aithority News : Marvell Bolsters Cloud-Optimized CXL Portfolio with Acquisition of Tanzanite

 [To share your insights with us, please write to sghosh@martechseries.com]